Red flag forces Cubist to halt Phase II enrollment

Cubist Pharmaceuticals slammed the brakes on enrollment for two mid-stage studies of ecallantide after the safety monitoring board noted a higher death rate among patients taking a high dose of the therapy to reduce bleeding during on-pump cardiac surgery. The move came one day after the FDA approved Dyax's ecallantide--to be marketed as Kalbitor--for hereditary angioedema. Cubist had in-licensed the drug.

The safety board raised the red flag for Cubist's CONSERV-2 trial, which is evaluating a high dose of the drug. Initial review shows mortality observed in the trial was due to a variety of causes typically expected in a high-risk-for-bleed population undergoing cardiac surgery, said the company in a statement. There was no such imbalance detected in the CONSERV-1 trial, also being monitored by the DSMB.

"When we designed Phase II to study ecallantide as therapy to reduce blood loss in on-pump cardiac surgery, we intentionally made it a robust program," said Cubist CEO Mike Bonney. "The CONSERV-2 trial in particular was intended to provide insight on all-cause outcomes in a higher risk cardiac surgery patient population. We will move as quickly as is prudent to analyze all the data from both CONSERV- 1 and CONSERV-2 in the first quarter."

- read Cubist's release
- here's the Reuters story

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Canadian biotech AbCellera has nabbed a meaty $105 million series B funding round as it looks to boost its antibody work and seek out new potential me